Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CXCR3-B could not induce cancer cell apoptosis at the optimal level when we either inhibited p38 activity or knocked down Bach-1.
|
24366869 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas ERK2 activation provides colon cancer cells with the ability to seed and colonize the liver, reduced p38 MAPK signalling endows cancer cells with the ability to form lung metastasis from previously established liver lesions.
|
24880666 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, LY2228820 is a p38 MAPK inhibitor, which has been optimized for potency, selectivity, drug-like properties (such as oral bioavailability), and efficacy in animal models of human cancer.
|
24356814 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elucidating the functions of specific substrates of JNK and p38 is therefore critical for our understanding of these kinases in cancer.
|
25456131 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.
|
24742967 |
2014 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition of p38 also decreased chemoresistant cancer tumor growth in xenograft animal models.
|
23403951 |
2013 |
Malignant Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We demonstrated that PtAcD (1) is more cytotoxic in cancer than in normal breast cells; (2) activated NAD(P)H oxidase, leading to PKC-ζ and PKC-α translocations; (3) activated antiapoptotic pathways based on the PKC-α, ERK1/2 and Akt kinases; (4) activated PKC-ζ and, only in cancer cell PKC-δ, responsible for the sustained phosphorylation of p38 and JNK1/2, kinases both of which are involved in the mitochondrial apoptotic process.
|
24030148 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results illustrate a new function of p38 MAPK that helps tumour cells to survive chemotherapeutic drug treatments, and reveal that the combination of p38 MAPK inhibitors with cisplatin can be potentially exploited for cancer therapy.
|
24115572 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LY2228820 dimesylate is a highly selective small molecule inhibitor of p38α and p38β mitogen-activated protein kinases (MAPKs) that is currently under clinical investigation for human malignancies. p38 MAPK is implicated in a wide range of biological processes, in particular those that support tumorigenesis.
|
23335506 |
2013 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Signaling mediated by p38 and JNK has well-established importance in cancer, yet the contribution of this pathway in urothelial bladder cancer is not understood.
|
22154358 |
2012 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data show that overexpression of Aurora-A contributes to the malignancy development of ESCC by enhancing tumor cell invasion as well as MMP-2 activity and expression, which can occur through signaling pathways involving p38 MAPK and Akt protein kinases.
|
22522455 |
2012 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest p38 inhibition as a potential way to increase the efficacy of treatments available for malignancies associated with deregulated SHH signaling, such as basal cell carcinoma and medulloblastoma.
|
22302101 |
2012 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study provides evidence for a role of OSU-DY7 in p38 MAPK activation and BIRC5 down regulation associated with apoptosis in B lymphocytic cells, thus warranting development of this alternative therapy for lymphoid malignancies.
|
21470196 |
2011 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Blocking ERK and p38 by a specific inhibitor significantly decreases cancer cell migration by inhibiting Runx2 up-regulation and subsequently attenuating the expression of Snail.
|
21885439 |
2011 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We propose that, in myeloid cells, the differential activation of p38 and NF-κB and induction of TRAIL, which sensitizes cells to apoptosis, can help to explain differences in responsiveness to IFN-β therapy among patients with RRMS and, furthermore, that such differential patterns of activation and expression may also be important in understanding the therapeutic responses to IFN-α/β in hepatitis and cancer.
|
22106296 |
2011 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p38 MAPK plays an important role in key cellular processes related to inflammation and cancer.
|
19852565 |
2009 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study provides new insight into the role of p38 MAPK in PKCalpha-mediated malignant phenotypes, especially in PKCalpha-mediated cancer cell invasion, which may have valuable implications for developing new therapies for some PKCalpha-overexpressing cancers.
|
17483345 |
2007 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Strategies merging functional genomic technologies are outlined for the identification of novel posttranscriptionally regulated targets of p38 to show that they are functionally linked to the induction or interruption of cellular growth in cancer.
|
18217689 |
2007 |